SYK vs VCEL
SYK: A diversified global MedTech leader providing surgical instruments, robotics, and advanced clinical technologies to enhance patient recovery and healthcare outcomes. VCEL: Vericel is a commercial-stage biotechnology company that develops and markets autologous cell therapies for the treatment of severe burns and cartilage damage in the knee.
Side-by-side fundamentals
| Metric | SYK | VCEL | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $276.97 | $40.05 | |
| Market cap | $106.2B | $2.1B | |
| P/E as of 2026-10-08 | 28.70 | 95.88 | SYK lower |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | 2.65 | n/a | |
| Net margin FY2025, SEC XBRL | +12.9% | +6.0% | SYK higher |
| Gross margin FY2025, SEC XBRL | +64.0% | +74.4% | VCEL higher |
| Operating margin FY2025, SEC XBRL | +19.5% | +4.0% | SYK higher |
| ROE FY2025, SEC XBRL | +14.5% | +4.7% | SYK higher |
| ROA FY2025, SEC XBRL | +6.8% | +3.4% | SYK higher |
| Debt / equity as of 2026-09-02 | 0.62 | 0.00 | VCEL lower |
| Revenue growth (YoY) as of 2026-09-02 | +8.5% | +22.9% | VCEL higher |
| Revenue CAGR (3y) SEC XBRL | +10.8% | +18.9% | VCEL higher |
| Dividend yield as of 2026-09-02 | +1.3% | n/a | |
| Dividend streak (yrs) SEC XBRL | 8 | 0 | SYK higher |
| Beta as of 2026-09-02 | 0.56 | 1.11 | |
| 1-year return as of 2026-10-08 close | -26.2% | +17.3% | VCEL higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.